Pharmacokinetics, Safety and Tolerability of BI 1015550 Following Oral Administration in Male and Female Participants With Different Degrees of Renal Impairment (Severe and Moderate) as Compared With Individually Matched Male and Female Participants With Normal Renal Function (an Open-label, Non-randomised, Single Dose, Parallel, Individual-matched Design Trial)
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 28 Aug 2023 Status changed from active, no longer recruiting to completed.
- 18 Aug 2023 Planned End Date changed from 16 Aug 2023 to 15 Aug 2023.
- 18 Aug 2023 Planned primary completion date changed from 16 Aug 2023 to 15 Aug 2023.